When is targeted radioisotope therapy recommended for neuroendocrine tumours?

Many neuroendocrine tumours carry receptors that can bind a specific tracer. A scan can show whether enough of that tracer reaches the tumour sites. If uptake is suitable, a radioactive isotope can be attached to the same type of carrier so radiation is delivered near those cells. This approach may be discussed when tumours cannot be removed completely, have spread, or continue to grow despite other options. The plan depends on tumour grade, location, scan findings, symptoms and earlier treatments.

Before treatment, the team checks blood counts, kidney function and general health. A nuclear medicine specialist and oncology team explain the expected benefits, uncertainties, other choices and monitoring required for the individual situation.

Bring a list of medicines and tell the team about kidney problems, pregnancy or breastfeeding, previous treatments and ongoing symptoms. Ask whether medicines that affect the tumour receptor need adjusting and how to maintain fluids. Plan for the radiation precautions given by the hospital, including contact arrangements, sleeping arrangements and bathroom guidance. Written instructions can help family members understand how to support you safely.

Contact the treatment team if you develop fever, unusual bleeding, severe vomiting, worsening abdominal pain, reduced urination or weakness that interferes with basic activities. Neuroendocrine tumours can also cause hormone-related symptoms; report flushing, diarrhoea, wheezing, dizziness or palpitations that are new or worse. Emergency help is needed for collapse, severe breathing difficulty or signs of a serious allergic reaction.

Ask what receptor or tracer finding supports treatment, how tumour grade affects the choice, what alternatives exist, how kidneys and blood cells will be monitored and what symptoms need urgent attention.